Close Menu

Regulus

NEW YORK (GenomeWeb) – Regulus Therapeutics last week posted its first-quarter financial results, reporting a sharp increase in its net loss on higher expenses.

Regulus Therapeutics this week announced the presentation of preclinical data showing that circulating microRNAs may be effective biomarkers for determining tumor growth and systemic response disease in liver cancer.

SAN DIEGO (GenomeWeb News) — MicroRNAs are cropping up in different aspects of cancer research, according to a session at the American Association for Cancer Research annual meeting held here this week.

A little less than a year after it lost its partner for its preclinical hepatitis C therapy RG-101, Regulus Therapeutics announced last week that AstraZeneca has stepped away from the companies' program to develop an atherosclerosis drug targeting microRNA-33.

Regulus Therapeutics this week announced that has formally added its preclinical program in the rare kidney disease Alport syndrome to its drug-development pipeline — a move widely expected based on company comments and recently released animal data linking microRNA-21 to the dis

Tekmira Pharmaceuticals has appointed Peggy Phillips to its board of directors.

Regulus Therapeutics this week announced that Sanofi has renewed the companies' strategic alliance to discover and develop microRNA therapeutics for cancer and certain orphan diseases.

Regulus Therapeutics has named David Szekeres as its chief business officer and general counsel.
In the new role, he will be responsible for business development, strategic planning, and legal efforts, Regulus said.

Regulus Therapeutics this week announced today that it has established a new research and development division that will focus on the identification of miRNAs as disease biomarkers.

The National Institutes of Health this month awarded more than $800,000 in research funding to support the work of four researchers, including two that have collaborated with Regulus Therapeutics, who are examining the role of microRNAs in various aspects of cardiovascular diseas

Pages

Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.

University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.

NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.

In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.